Market revenue in 2023 | USD 50.9 million |
Market revenue in 2030 | USD 94.3 million |
Growth rate | 9.2% (CAGR from 2023 to 2030) |
Largest segment | Phase iii |
Fastest growing segment | Phase I |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III, Phase IV |
Key market players worldwide | Thermo Fisher Scientific Inc, IQVIA Holdings Inc, Clara Health, Antidote Health, BBK Worldwide, Clariness, Costas Inc, Worldwide Clinical Trials, Veristat, Elligo Health Research |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to clinical trial patient recruitment services market will help companies and investors design strategic landscapes.
Phase iii was the largest segment with a revenue share of 57.37% in 2023. Horizon Databook has segmented the China clinical trial patient recruitment services market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
China is one of the major clinical trial markets in the Asia Pacific, owing to the availability of skilled professionals, cost-efficiency, and the growing pharmaceutical industry. According to Globaldata, China accounted for 27.7% of global clinical trials conducted in 2022, which is expected to grow significantly over the forecast period.
Outsourcing of clinical services to China has also increased due to the costefficiency provided by Chinese CROs as compared to that by U.S. and European CROs. For instance, the cost of conducting clinical trials in China is 25% to 40% lower than that of Western countries.
The above factors are expected to improve clinical trials in the country and, thus, support the demand for clinical trial patient recruitment services in China. CR Medicon, a China-based CRO, stated that China is preferred for conducting clinical trials due to its high patient recruitment rate.
Horizon Databook provides a detailed overview of country-level data and insights on the China clinical trial patient recruitment services market , including forecasts for subscribers. This country databook contains high-level insights into China clinical trial patient recruitment services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account